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Summary Immunosuppression has been often associated with the course ofmalignant diseases. In the present
study, the proliferation of peripheral blood mononuclear cells (PBMCs) in response to mitogenic stimulation
wvith phytohaemagglutinin (PHA) was assessed prospectively in 90 patients with stage I-III breast cancer.
Whereas PHA-induced proliferation of PBMCs derived from patients with breast cancer preoperatively was
significantly decreased when compared with data obtained in healthy control individuals (P<0.001), the
degree of the defect in PHA-induced proliferation of PBMCs depended upon the tumour burden as manifested
by tumour size and axillary lymph node involvement (P<0.003 in each case). PHA-induced proliferation of
PBMCs dropped significantly in patients who received adjuvant chemotherapy consisting of cyclophos-
phamide, methotrexate and fluorouracil (CMF) after an observation penrod of 6 months (P<0.01), but not in
patients under adjuvant treatment with tamoxifen only. After an additional 6 months (i.e. 12 months after
surgery). PHA-induced proliferation of PBMCs was similar in patients after adjuvant chemotherapy with
CMF and in those receiving continued adjuvant tamoxifen treatment (P>0.1). but in all patients still
significantly decreased as compared with healthy controls (P<0.001). When data obtained preoperatively and
after 12 months were compared. it was found that out of 23 patients whose PBMCs had expenrenced a drop in
their PHA-induced proliferation. 14 (61%) had developed metastatic disease within the subsequent 24 months
(i.e. 36 months after surgery). In contrast, out of 59 patients whose PBMCs showed an increase in their
PHA-induced proliferation within the first 12 months after surgery. only one (2%) presented with disease
progression. We thus conclude that PHA-induced proliferation of PBMCs derived from patients with breast
cancer depends upon the tumour load and is a good clinical predictor for the further course of the disease.
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Several studies have demonstrated that patients with cancer
as well as experimental animals with transplanted tumours
show a decrease in delayed-type hypersensitivity (DTH) reac-
tions and experience cutaneous anergy (Stein et al., 1976;
Broder and Waldmann, 1978; Giuliano et al., 1979). This fact
was attributed to an induction of suppressor cells (Kirchner,
1978; Yu et al., 1977; North and Bursuker, 1984), the
emergence of soluble suppressive factors (Whittaker et al.,
1971; Nimberg et alt, 1975; North et alt, 1984) or to a lack of
lymphokines (Fearon et alt, 1990) associated with the
development of neoplasms. Consequently, impressive results
were achieved by the induction of lytic effector T-cell func-
tion by interleukin 2 (IL-2), leading to the establishment of
lymphokine-activated killer cell therapy in patients with
various malignancies.
Established prognostic markers in breast cancer include
mainly tumour-associated characteristics such as the number
of involved axillary lymph nodes, tumour size, oestrogen
receptor status and oncogene overexpression (Clark and
McGuire, 1988; Contesso et al., 1989), but no immunological
characteristics of tumour or host. A series of studies have
been performed to investigate the latter aspect (Penn, 1982.
1988; Zielinski et al.. 1989a; Knogler et al., 1992). The
majority of these studies have dealt, however, with certain
functions of the immune system assessed at single time points
during the course of the disease and are thus of limited value,
as both, chemo- and radiotherapy can exert considerable
influence upon the parameters measured (Whittaker et al..
1971; Stein et al.. 1976; Vose and Moore. 1980: Uchida and
Hoshino, 1980; Cunningham-Rundles et al., 1981; White et
al., 1982; Tichatschek et alt, 1988). Moreover, many of the
studies on immune function in patients with breast cancer
have utilised sophisticated methods which are not available
within the routine clinical setting. Based on these considera-
tions, we have decided to study prospectively and lon-
gitudinally proliferative responses of peripheral blood
mononuclear cells (PBMCs) stimulated with phytohaemagg-
lutinin (PHA), which is an easily applicable, widely used and
accepted assay giving reproducible and easily quantifiable
data. Results from these experiments were correlated with
tumour status and the course of the disease. We report that
the initial proliferation of PBMCs in response to PHA
depended upon the tumour load and that, furthermore, the
longitudinal assessment of PHA-induced proliferation of
PBMCs constituted a good prognostic marker for the
development of metastatic disease.
Materials and methods
Patients and clinical variables
Ninety female patients (mean age 54 ± 2.3 years) were
included in this study. The patients were all diagnosed as
having stage I (eight patients), II (53 patients) or III (29
patients) breast cancer between October 1988 and December
1991. Patients with metastatic (i.e. stage IV) disease were
excluded from the study. After surgery, all patients with
stage II and III disease were included consecutively in a
clinical treatment protocol of adjuvant therapy randomising
between treatment with either cyclophosphamide, methotrex-
ate and fluoruracil (CMF: Bonadonna et al., 1977) for 6
months, endocrine treatment with tamoxifen (20 mg daily;
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Mikl et al., 1990; EBCTCG, 1992) for 2 years or combined
chemotherapeutic plus endocrine (i.e. tamoxifen) treatment.
Only patients >70 years were excluded from the treatment
protocol with all others being treated according to the pro-
tocol. Adjuvant treatment started within 3 weeks after
surgery. Although all patients with stage I-III disease
ived radiotherapy to the operated breast, patients with
stage I disease did not receive any further adjuvant treatment
with either CMF or tamoxifen.
Collection ofblood sanples
Blood samples were colhected by venous puncture into tubes
containing preservative-free heparin before surgery and 3 and
12 months after surgery or follow-up. The time point of 12
months after surgery equalled 6 months after termination of
adjuvant chemotherapy in patients who had received CMF.
For the collection of sera, blood was drawn into tubes which
did not contain any addition.
Controls
PBMCs from 60 and sera from six healthy age-matched
females (mean age 55 ± 3.2 years) served as controls.
Pathologial andbiochemical analysis oftissue smples
Pathological diagnosis was made on paraffin-embedded speci-
mens of tissue obtained during surgery using routine
methods. Hormone receptor status was asd by
biochemical means, as described previously (Zieislki et al.,
1989a).
Isolation ofperipheral blood mononuclear cells (PBMCs)
PBMCs were gained by centrifugation of whole heparinised
venous blood over a Ficoll-Hypaque (Ficoll-Paque, Phar-
Uppsala, Sweden) density gradient and subsequently
resuspended in RPMI-1640 (Gibco) supplemented with
100IU of penicillin and l00 tgml-' streptomycin and
adjusted to 1 x 106 PBMCs ml-'.
Mitogenic stimulation with PHA
Cell cultures were performed as described previously (White
et al., 1982). Briefly, 1 x I0O PBMCs suspended in 1001id of
RPMI-1640 were pipetted into microtitre plates and PHA
added to final concentrations of lOpg ml-', 50pgml-' and
100gml-1' respectively. All assays were performed in tri-
plicate for each patient and for each PHA concentration.
Healthy age-matched females served as controls to circum-
vent a possible influence of steroids through changes in the
pool size of radioactivity. The cultures were incubated at
37C in a humidified atmosphere containing 5% carbon diox-
ide for a total of 96 h. Sixteen hours before the end of the
incubation period, 100#1 of supplemented medium contain-
ing 20p11 of [3H]thymidine (185GBqmmol-'; Amersham,
UK) was added. The cells were harvested with an automatic
harvester, and the resulting radioactivity was determined by
liquid scintillation in a beta counter.
In order to analyse the influence of sera of patients with
breast cancer upon lymphocyte proliferation, PBMCs derived
from healthy individuals were preincubated with sera diluted
1:10 or 1:100 (v/v), respectively, at 3TC for 3 h and submit-
ted subsequently to PHA assays as above.
Characterisation ofsuppressivefactors in sera
Sera were obtained from (i) six healthy controls and (ii) from
nine patients with metastatic breast cancer following surgery.
Sera were diluted 1:2 in phosphate-buffered saline and sub-
jected to ultrafiltration through Amicon CF 25 Centriflow
cones (Amicon, Danvers, MA, USA) for 15 min at 800 g
(mol. wt cut-off point 25 kDa) at room temperature. PBMCs
were isolated as described previously and resuspended to a
concentration of I x 10' lymphocytes per ml of supplemented
RPMI-1640. Approximately I0W PBMCs per well were cul-
tured with 1001I of either unseparated sera or their low or
high moklular weight fractions in final dilutions of 1:10 or
1:100 for I h at 3TC. Subsequently, PBMCs were stimulated
with 201L of PHA (HA 15, Murex) and incubated for 4 days
at 3TC in a humidified atmosphere contiing 5% carbon
dioxide.
Statistical methods
If not specified otherwise, data are presented as mean ± s.d.
Statistics were done by X2 and Student's t-test for paired
data.
Res
Mitogenic stmlation with PHA in patients with breast cancer
Table I shows the results of assays evaluating PHA stimula-
tion of PBMCs derived from patients with stage I-IlI breast
cancer at the time of their diagnosis. In general, PBMCs
derived from patients with breast cancer had a significantly
lower proliferative rate in response to PHA than those from
healthy control individuals (P<0.001). Moreover, this
decrease in mitogenic stimulation depended on the stage of
the disease, i.e. a clear correlation between the stage of the
disease and the level of proliferation of PBMCs in response
to PHA was found (P<0.001 between all stages of the
diseas, Table I).
Correlation ofmitogenic stimulation ofPBMC with other
clinical parameters in breast cancer
Table II shows that a clear correlation of the PHA-induced
proliferation of PBMCs derived from patients with breast
cancer was found with tumour size (P<0.0035) and the
number of involved lymph nodes (P<0.003), but not with
Table I PHA-stimulation in patients with stage I-III breast cancer
at the time of diagnosis and in healthy controls
n c.pm.' P-vahle
All breast cancer patients 90 41.5 12.5 <O.OOlb
Stage I 8 52.7 8.2 <0.001
Stage II 53 44.7 11.2 <0.001
Stage III 29 32.5 ± 10.3 <0.001
Healthy controls 60 92.4 16.4
aCounts per minute in PBMC stimulation assays using PHA.
bVersus data obtained in healthy controls.
Tae H Correlation of mitogenic stimulation measured pre-
operatively with other clinical parameters
C.p.M P-valu
Tumour size (cm)
<2 45.3 ± 12.4 0.0035
>2 31.4± 10.0
Lymph nodes
negative 49.7 11.6 0.003
positive 32.9 ± 12.8
Oestrogen receptor (ER)
ER positive 40.2 14.2 0.011
ER negative 36.7 ± 14.0
Progesterone receptor (PgR)
PgR positive 40.1 ± 12.6 0.016
PgR negative 36.9 9.8
Menopausal status
Premenopausal 35.3 10.0 NSb
Post-menopausal 41.2± 13.4
'Counts per minute in PBMC stimulation assays using PHA. bNot
significant.
1
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hormone receptor status (oestrogen or progesterone receptor)
or age.
Influence ofadjuvant therapy upon mitogenic stimulation of
PBMCs
As shown in Figure 1, adjuvant chemotherapy with CMF
reduced mitogenic stimulation in patients with stage 1-111
breast cancer significantly. While PBMCs derived from all
patients who received adjuvant CMF treatment showed a
further decrease in their proliferation in response to PHA
after 6 months of therapy as compared with pretreatment
levels (P<0.001), neither patients under endocrine treatment
nor patients who did not receive any adjuvant drug treatment
(i.e. patients with stage I disease) presented with similar data
(P>0.1).
When patients who received adjuvant CMF treatment were
studied further for the proliferative rate of their PBMCs in
response to PHA, the decrease seen after 6 months had
vanished after an additional 6 months (Figure 1). Thus, 12
months after surgery, i.e. 6 months after termination of
adjuvant chemotherapy with CMF, PBMCs from patients
who had received either adjuvant chemotherapy or adjuvant
endocrine treatment or no adjuvant treatment at all present-
ed with similar mean proliferative responses in response to
PHA.
Prognostic value ofPBMCproliferation 12 months
post-operatively in patients with breast cancer
In a further analysis, the course of proliferation of PBMCs in
response to PHA before the initiation of treatment and after
12 months was analysed prospectively and put into context
with disease status after a total of 36 months.
Twelve months after surgery, 82 patients had remained
without evidence of disease, as assessed by clinical means. Of
these patients, 15 showed progressive disease after 36
months, whereas 67 patients had remained disease free.
Owing to a great variability between the patients, the
absolute mitogenic stimulation of PBMCs assessed neither
preoperatively nor after 12 months showed significant prog-
nostic relevance. Nevertheless, when the change in lym-
phocyte proliferation after this mitogenic stimulation was
compared with the clinical outcome after 3 years, a
significant correlation was seen. Patients who were to remain
in complete remission for 36 months showed an increase in
the proliferative responses of their PBMCs in response to
PHA after 12 months of 15.9 ± 24.7%, whereas patients with
future progressive disease showed a further decline from their
initial level of proliferation by 26.5 ± 14.1% (P<0.001).
This pattern was found in patients with various initial stages
of breast cancer (Table III) and was independent of the kind
















Figwe I Influence of adjuvant therapy upon mitogenic stimula-
tion of PBMCs. c.p.m.. counts per min; , adjuvant endocrine
therapy (tamoxifen); ..., CT adjuvant chemotherapy
(CMF = cyclophosphamide. methotrexate. fluouracil); ---, no
adjuvant therapy.
Influence ofpatients' sera upon PBMC proliferation
In order to evaluate the possibility of a soluble factor
secreted by the tumour or other soluble factors present in the
sera of patients with metastatic breast cancer, PBMC pro-
liferation assays were performed in the presence of sera
derived from patients with untreated metastatic breast
cancer. Although there was a tendency in data from which
one could suspect a suppressive influence of the diluting
agent itself, there was no significant difference between PHA
stimulation of PBMCs with or without control sera in
different dilutions. In contrast, sera derived from patients
with untreated metastatic breast cancer in contrast
significantly inhibited the proliferation of control PBMCs in
a dilution-dependent manner (serum dilution 1:10, P<0.001;
1:100, P> 0.1). Table IV shows the results of two represen-
tative experiments out of the performed six assays. Table V
shows the successful enrichment by ultracentrifugation of the
factor(s) responsible for the suppression of PBMC prolifera-
tion in the protein fraction below 25 kDa. This serum
preparation resulted in the most effective suppression of PHA
stimulation which could not be reversed by dilution (Table
V).
Table m Correlation of clinical course with changes in PHA-
induced stimulation of PBMCs (preoperative values compared with
data obtained after 12 months) in patients with stage I-III breast
cancer with complete remission after 36 months (n = 82)
Change in mitogenic
Disease status stimulationa Fishers exact
Group at 36 months Increase Decrease test (two-tailed)
Total CR 9 58 <0.0001
PD 14 1
Stage
I CR 2 6
PD - -
II CR 5 39 0.0027
PD 4 1
III CR 2 13 <0.0001
PD 10 -
Overall sensitivity, 93.30%; overall specificity, 86.70%; positive
predictive value, 0.6087; Negative predictive value. 0.9831.
'Mitogenic stimulation with phytohaemagglutimnn.
Table IV Influence of sera derived from patients with untreated
metastatic breast cancer upon PHA-induced proliferation of PBMCs
derived from healthy control individuals
Experiment Serwn Dilution c.p.m.3
1 0 82.6 10.5
Control 1:10 86.8 6.1
1:100 78.2 4.0
Patient 1:10 31.6 7.4
1:100 85.8±4.5
2 0 102.3±11.8
Control 1:10 94.7 10.5
1:100 85.9 5.7
Patient 1:10 27.2 ± 7.2
1:100 95.0 9.9
aCounts per minute in PBMC stimulation assays using PHA.
Table V Characterisation of the factor(s) present in sera of patients
with breast cancer which are responsible for the inhibition of PBMC
proliferation
Nwnber of
experiments Serum fraction Dilution c.p.m.
4 Control sera. 1:10 75.8± 14.3
unfractionated 1:100 82.3 15.9
6 Patients' sera. 1:10 36.7±8.3
unfractionated 1:100 44.7 7.6
6 Patients' sera 1:10 35.9 7.0
>25kDa 1:100 40.3 9.4
6 Patients' sera 1:10 14.3 3.0





Correlation ofthe proliferative status ofPBMCs in response to
PHA with the clinical status after 3 years
The data presented in Table III show that, of 59 patients
who presented with an increase in the proliferative ability of
their PBMCs to PHA when preoperative data and values
obtained after 12 months were compared, 58 (98%) eaine
in complete remission for a total of 3 years. In contrast, of
23 patients with a decrease in the proliferation of their
PBMCs in response to PHA within 12 months, only nine
(39%; P<0.0001) remained in complete remission for 3
years, whereas the remaining 14 patients (61%) developed
metastatic disease. As shown in Table III the correlation
remains significant when adjusted to disease stage (stage II,
P=0.0027; stage III, P<0.001). These data result in an
overall sensitivity of 93.3% and an overall specificity of
86.7%. Adjusting for stage did not alter estimates. Thus,
PHA stimulation studied longitudinally constituted an impor-
tant new parameter.
The present study was performed in order to analyse pros-
pectively and longitudinally the course of PHA-induced
stimulation of PBMCs derived from patients with brast
cancer during and after adjuvant chemotherapy or endocrine
treatment. Moreover, we studied whether the results from
assays investigating PHA-induced stimulation of PBMC had
a prognostic and predictive value for the further course of
breast cancer. In following these aims, blood sampls were
obtained from each patient before surgery and 6 as well as 12
months thereafter. Independent of the current investigational
protocol, patients had been randomised after surgery to
receive either adjuvant chemotherapy according to the CMF
protocol or tamoxifen or both (EBCTCG, 1992). It was
found tht PHA-induced stimulation of PBMCs derived from
patients with breast cancer before surgery was significantly
lower than in PBMCs from healthy control individuals and
correlated with the stage of the disease, including tumour size
and lymph node status, i.e. the tumour burden. Although a
transient drop in PHA-induced proliferation of PBMCs
derived from patients undergoing CMF treatment was noted,
12 months after surgery the mean results of PBMC prolifera-
tion assays were similar in all patient groups (i.e. those 6
months after termination of CMF treatment or during
tamoxifen therapy or both). However, also at this point of
time, data obtained in patients with breast cancer were
significantly lower than those from healthy controls, as
reported previously by other authors (Whittaker et al., 1971;
Stein et al., 1976).
Our data demonstrated, finally that, irrespective of the
kind of adjuvant treatment, two-thirds of patients whose
PBMCs showed a drop in their PHA-induced proliferation
within 1 year experienced rapid recurrence of disease. This
fact was fiuther corroborated by the observation that breast
cancer did not recur within the observation period in patients
whose PBMCs showed an increase in PHA-induced prolifera-
tion.
Tlhe results presented in the current report pose a series of
questions. Thus, the persistent decrease in PHA-induced pro-
liferation of PBMCs derived from patients with breast cancer
has to be explained. Considering our data there could be
several reasons for this finding. The initial decrease in lym-
phocyte proliferation could be due to the presence of the
tumour and its influence upon the immune system. Such
assumptions can be made on the basis of data obtained in
humans with cancer as well as in experimental animals which
demonstrated decreased DTH and a defect in lymphocyte
proliferation in the presence of neoplastic tissue (Stein et al.,
1976; Broder et al., 1978; Giuliano et al., 1979). Several
reasons have been discussed for these findings, including
defective lymphokine production and an increase in the prod-
uction of suppressor factors by the tumour (Whittaker et al.,
1971; Nimberg et al., 1975; North et al., 1984; Mizoguchi et
al., 1992).
Previous studies by other investigators (Whittaker et al.,
1971; Nimberg et al., 1975; Giuliano et al., 1979; North et
al., 1984; Mizoguchi et al., 1992) as well as our data would
favour the second possibility, as the exogenous addition of
recombinant interleukin 2 to cultures of lymphocytes derived
from patients who had presented with defective proliferation
previously in our experiments did not have any enhancing
influence upon lymphocyte function (data not shown). In
contrast, the addition of sera derived from patients with
metastatic breast cancer to lymphocytes derived from healthy
control individuals produced a significant decrease in PHA-
induced proliferation, thus suggesting the presence of one or
more suppressive factors of a molecular weight below
25 kDa. Although this explanation could be also considered
for the finding of a decrease in lymphocyte proliferation in
patients who were to develop metastatic disease within the
subsequent 2 years, additional variables, including the induc-
tion of suppressor cells by the emergng tumour (Yu et al.,
1977; North et al., 1984) or an alteration in signal transduc-
tion moleules (Mizoguchi et al., 1992), must be considered.
The problem could be further aggravated by the fact that
adjuvant cytostatic treatment with CMF has previously been
demonstrated in studies in this laboratory to lead to a pro-
longed defect in the production of a primary immune res-
ponse following vaccination (Zielinski et al., 1986) and
lymphocyte proliferation (Knogler et al., 1992) as well as
lymphokine production (Zielinski et al., 1986, 1989b). The
latter aspects also constitute the most likely explanations for
the decrease in PHA-induced lymphocyte proliferation under
immediate CMF therapy seen in the present study.
Clinically, the decrease in lymphocyte proliferation in two-
thirds of patients who were to develop metastases within the
relatively near future ckarly constitutes a new prognostic
tool for the prediction of the development of early metastatic
disease. Neverthekss, owing to the relatively small number of
patients and short follow-up times, the ultimate prognostic
value of this phenomenon has to be proven in a largr study,
which is ongoing in our institute. Although previous studie
on a similar question have failed to find such a prognostic
value for PHA stimulation (Stein et al., 1976; Nordman et
al., 1985) in solid tumours, it is an accepted predictive
parameter in Hodgkin's disease (Bj6rkholm et al., 1982;
Wedelin et al., 1982). However, the lack of such a finding in
patients with solid tumours may be due to the heterogeneity
of studied patients so far. Nevertheless, the fact is surprisng,
as immunological variables have not been used until now as
either prognostic tools or for the design of adjuvant trials.
However, several studies have demonstrated a clear assoca-
tion of lytic effector lymphocyte function and such estab-
lished prognostic variables as tumour load (Contesso et al.,
1989), oestrogen receptor status (Clark et al., 1988) and
amplification of the HER-2neu oncogene (Zeillinger et al.,
1989).
Although further studies and the use of more sophisticated
stimulants of lymphocyte proliferation than the widely
available PHA assay including the use of anti-CD3
antibodies will have to corroborate and extend our results,
the results presented in the current report could lead to such
clinical consequences as lymphokine treatment or the
repeated use of a series of adjuvant cytostatic therapies in
expanded time intervals or in selected patients who fulfil the
appropriate immunological criteria.
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